Delving into the Latest Updates on Maru Therapeutics Co., Ltd. with Synapse

概览

疾病领域	数量

免疫系统疾病	1

排名前五的药物类型	数量

CAR-NK	1

关联

7

项与 Maru Therapeutics Co., Ltd. 相关的药物

MARU-203

靶点-

作用机制

自然杀伤细胞替代物

在研机构

Maru Therapeutics Co., Ltd.

原研机构

Maru Therapeutics Co., Ltd.

在研适应症

狼疮性肾炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

MARU-101

靶点-

作用机制

T淋巴细胞替代物

在研机构-

原研机构

Maru Therapeutics Co., Ltd.

在研适应症-

非在研适应症

急性淋巴细胞白血病 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

MARU-102

靶点-

作用机制

T淋巴细胞替代物

在研机构-

原研机构

Maru Therapeutics Co., Ltd.

在研适应症-

非在研适应症

实体瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Maru Therapeutics Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Maru Therapeutics Co., Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Maru Therapeutics Co., Ltd. 相关的文献（医药）

2024-03-22·Cancer Research

Abstract 1330: Universal and potent chimeric antigen receptor-natural killer (upCAR-NK) cells for B-cell malignancy treatment

作者: Han, Mijung ; Kang, Kyung-Sun ; Moon, Bo Kyung ; Lee, Ji-Han ; Lee, Tae-Wook ; Kwon, Daekee

AbstractPatient-specific CAR-T cells treatment is an innovative new drug that has shown excellent therapeutic effects against B cell blood cancer. However, side effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome and ultra-high treatment costs must be overcome, and off-the-shelf CAR-NK cells can be a good alternative. The purpose of this study was to combine cellular reprogramming, gene editing, and differentiation technologies to produce full-off-the-shelf NK cells derived from iPSCs and verify their efficacy and safety. To this end, somatic cell-derived iPSCs were produced, seven genes were edited using CRISPR/Cas9 technology (5 kinds of knockout and 2 kinds of overexpression), and differentiated into NK cells. upCAR (universal and potent chimeric antigen receptor)-iPSCs with seven genes edited showed bialleic INDEL in the coding sequence of five genes and no off-target effect. In addition, normal transcriptome and genetic stability were maintained. High-efficiency differentiated upCAR-NK cells showed a very high differentiation yield, in vitro proliferation, and freezing/thawing were possible. In addition, upCAR-NK cells secrete interferon-γ when they meet cancer cells, showing cytotoxic effects in vitro and in vivo. upCAR-NK cells themselves showed no obvious toxicity in vivo. In conclusion, this study developed upCAR-iPSCs and upCAR-NK cells platform technologies that are less likely to have side effects and can be economically developed for B cell blood cancer than CAR-T. In the future, this technology can be useful in developing full-off-the-shelf CAR-NK cells anti-cancer immune cell therapy with low side effects, high efficacy, and low price.Citation Format: Daekee Kwon, Bo Kyung Moon, Mijung Han, Tae-Wook Lee, Ji-Han Lee, Kyung-Sun Kang. Universal and potent chimeric antigen receptor-natural killer (upCAR-NK) cells for B-cell malignancy treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1330.

100 项与 Maru Therapeutics Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Maru Therapeutics Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

6

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MARU-203	狼疮性肾炎更多	临床前
MARU-101	急性淋巴细胞白血病更多	终止
MARU-102	实体瘤更多	终止
MARU-202	胶质母细胞瘤更多	未知
MARU-301	实体瘤更多	未知